Source comparison
Thymosin Alpha-1 Studied Rheumatoid Arthritis: Trial Comparison
Tongji Medical College 2019 42 patients 12 weeks Thymosin alpha-1 1.6mg BIW + MTX vs MTX alone DAS28-ESR reduction Not reported Modest DAS28 improvement; no remission data Rheumatology International 2021 56 patients 24 weeks Thymosin alpha-1 1.6mg BIW + DMARD
This comparison does not assign a generated winner or score.
- Tongji Medical College 2019
- 42 patients
- 12 weeks
- Thymosin alpha-1 1.6mg BIW + MTX vs MTX alone
- DAS28-ESR reduction
- Not reported
- Modest DAS28 improvement; no remission data
- Rheumatology International 2021
- 56 patients
- 24 weeks
- Thymosin alpha-1 1.6mg BIW + DMARD vs DMARD alone
- ACR20 at 24 weeks
- 31% vs 18%
- Statistically significant but clinically modest; no ACR50 achieved
- Shanghai Renji Hospital 2018
- 38 patients
- 16 weeks
- Thymosin alpha-1 + leflunomide vs leflunomide alone
- Change in synovial Treg/Th17 ratio
- Not applicable
- Biological endpoint only; no clinical response data